Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CND261 in Seropositive Rheumatoid Arthritis
NCT07052032Phase 1Active, not recruiting
- Sponsor
- Candid Therapeutics
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of CND261 in rheumatoid arthritis (RA), sponsored by Candid Therapeutics. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 12 months, Changes from baseline in vital signs at 12 months and 4 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
CND261
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07052032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052032.